Berlin - Delayed Quote EUR

Celsion Corp (CBO.BE)

1.6100

+0.0300

+(1.90%)

As of 8:08:18 AM GMT+2. Market Open.

Imunon, Inc. (IMNN) Raises $3.25M in Private Placement, Eyes $6.5M More

Imunon, Inc. (NASDAQ:IMNN) has completed a private placement, securing $3.25 million in initial funding by selling 7,222,223 shares of common stock or pre-funded warrants at $0.45 each. The deal also grants investors short-term warrants to buy up to 14,444,446 additional shares at the same price. If all warrants are exercised within three years after shareholder […]

Insider Monkey yesterday

IMNN
IMUNON Closes Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants LAWRENCEVILLE, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today closed on the previously announced sale of an aggregate of 7,222,223 shares of its common stock (or pre-funded warrants in lieu therof) and short-term warrants to purchase up to an

GlobeNewswire yesterday

IMNN
Imunon announces up to $9.75M private placement priced at-the-market

Imunon (IMNN) announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 7,222,223 shares of its common stock or pre-funded warrants in lieu therof and short-term warrants to purchase up to an aggregate of 14,444,446 shares of common stock at a purchase price of 45c per share or pre-funded warrant in lieu thereof and accompanying short-term warrants in a private placement priced at-the-market under Nasdaq rules. The warrants will be exercisable beginnin

TipRanks 2 days ago

IMNN
IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025

Presentation at ESMO will follow oral 2025 ASCO Annual Meeting presentation highlighting unprecedented survival data from Phase 2 OVATION 2 Study of IMNN-001 Simultaneously publication in leading peer-reviewed journal Gynecologic Oncology details IMNN-001’s outstanding safety and efficacy across multiple analyses and subgroups Treatment with IMNN-001 could represent new promise for estimated 40,000 women newly diagnosed with advanced ovarian cancer yearly in EU and 300,000 globally LAWRENCEVILLE

GlobeNewswire 2 days ago

IMNN
IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants LAWRENCEVILLE, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 7,222,223 shares of its common stock (or pre-funded warrants in lieu therof) an

GlobeNewswire 6 days ago

IMNN
Sector Update: Health Care Stocks Decline Late Afternoon

Health care stocks retreated late Friday afternoon, with the NYSE Health Care Index down 0.2% and th

PREMIUM
MT Newswires 6 days ago

BCAX

IMNN
IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer

Data show continuous clinically significant improvement, with median 13-month and 3-month increases in overall and progression-free survival, respectively, in treatment group Women treated with IMNN-001 and standard of care chemotherapy plus PARP inhibitors achieved nearly 12-month increase in PFS compared to standard of care; median OS in IMNN-001 treatment arm not yet reached after more than five years Phase 2 OVATION 2 Study results also published in peer-reviewed journal Gynecologic Oncology

GlobeNewswire 6 days ago

IMNN
IMUNON Announces Withdrawal of Form S-1 Registration Statement

LAWRENCEVILLE, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has filed a request for withdrawal with the Securities and Exchange Commission (SEC) of the Company’s Registration Statement on Form S-1 (No. 333-286403), as amended, originally filed on April 4, 2025 (Registration Statement), as the Company no longer intends to pursue a public offering under the Registrati

GlobeNewswire 7 days ago

IMNN
IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19

Company’s PlaCCine® technology platform demonstrates better durability and other advantages compared to mRNA vaccines Results further validate PlaCCine as a novel vaccine platform with potential applications in COVID-19 and other infectious diseases with epidemic implications LAWRENCEVILLE, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapies and evaluating an adaptation of the platform’s potenti

GlobeNewswire 14 days ago

IMNN
IMNN: First Site Activated for Phase 3 OVATION 3 Trial…

By David Bautz, PhD NASDAQ:IMNN READ THE FULL IMNN RESEARCH REPORT Business Update First Site Activated for Phase 3 OVATION 3 Trial of IMNN-001 in Ovarian Cancer On May 8, 2025, Imunon, Inc. (NASDAQ:IMNN) announced that the first trial site for the Phase 3 OVATION 3 trial has been activated and is ready to begin enrolling patients. During the quarterly update conference call, management indicated

Zacks Small Cap Research 15 days ago

IMNN
Imunon Inc (IMNN) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

Imunon Inc (IMNN) progresses with pivotal Phase 3 trials while navigating financial hurdles and seeking strategic partnerships.

GuruFocus.com 17 days ago

IMNN
IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update

First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer New data from Phase 2 OVATION 2 study of IMNN-001 accepted for oral presentation at 2025 ASCO Annual Meeting Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today reported financial results for the three mont

GlobeNewswire 17 days ago

IMNN
IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Company currently initiating additional trial sites and working with study investigators to enroll participants IMNN-001 is the first and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in women with advanced ovarian cancer Data from Phase 2 OVATION 2 Study are encouraging, with new IMNN-001 data to be highlighted in oral presentation at 2025 ASCO Annual Meeting LAWRENCEVILLE, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage c

GlobeNewswire 21 days ago

IMNN
IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology

Data from OVATION 2 trial will also be reviewed in an oral presentation at ASCO Annual Meeting on June 3, 2025 LAWRENCEVILLE, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced that data from the company’s Phase 1/2 OVATION 2 trial evaluating intraperitoneal IMNN-001 in combination with neoadjuvant and adjuvant chemotherapy in newly diagnosed patients with advanced epithelial

GlobeNewswire 23 days ago

IMNN
IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025

LAWRENCEVILLE, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will host a conference call at 11:00 a.m. ET on Monday, May 12, 2025 to discuss financial results for the first quarter ended March 31, 2025 and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy, including progress in advancing the IM

GlobeNewswire 24 days ago

IMNN
IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting

Highly promising survival data from OVATION 2 Study of treatment of newly diagnosed advanced ovarian cancer to be presented Initiation of Phase 3 trial sites underway for pivotal study of IMNN-001 following alignment on protocol with FDA LAWRENCEVILLE, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that an abstract highlighting new, highly encouraging, Overall Survival data f

GlobeNewswire last month

IMNN
IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer…

By David Bautz, PhD NASDAQ:IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer On March 24, 2025, Imunon, Inc. (NASDAQ:IMNN) announced it reached alignment with the U.S. FDA on the protocol for a Phase 3 clinical trial, referred to as OVATION 3, of its lead candidate IMNN-001 for the treatment of women with newly diagnosed

Zacks Small Cap Research 2 months ago

IMNN
FDA aligns with Imunon’s Phase III trial protocol for ovarian cancer treatment

Imunon is initiating sites for the trial and collaborating with investigators to commence participant enrolment.

Clinical Trials Arena 2 months ago

IMNN
IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation of trial sites underway for ground-breaking Phase 3 pivotal trial of DNA-mediated IL-12 therapeutic Company to hold conference call on Tuesday, March 25, 2025, at 2:00 p.m. ET LAWRENCEVILLE, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today anno

GlobeNewswire 2 months ago

IMNN
IMNN: Phase 3 Ovarian Cancer Trial to get Underway in Mar 2025…

By David Bautz, PhD NASDAQ:IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Phase 3 Ovarian Cancer Trial to Initiate in March 2025 Imunon, Inc. (NASDAQ:IMNN) is continuing preparations to conduct a Phase 3 clinical trial of its lead development compound, IMNN-001, in patients with advanced ovarian cancer. IMNN-001 is a DNA immunotherapeutic drug that consists of an interleukin (IL)-12

Zacks Small Cap Research 2 months ago

IMNN

Performance Overview

Return	CBO.BE	S&P 500 (^GSPC)
YTD	+116.11%	+0.52%
1-Year	+22.90%	+12.93%
3-Year	-27.48%	+42.18%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Celsion Corp (CBO.BE)

Imunon, Inc. (IMNN) Raises $3.25M in Private Placement, Eyes $6.5M More

IMUNON Closes Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Imunon announces up to $9.75M private placement priced at-the-market

IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025

IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sector Update: Health Care Stocks Decline Late Afternoon

IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer

IMUNON Announces Withdrawal of Form S-1 Registration Statement

IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19

IMNN: First Site Activated for Phase 3 OVATION 3 Trial…

Imunon Inc (IMNN) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update

IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology

IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting

IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer…

FDA aligns with Imunon’s Phase III trial protocol for ovarian cancer treatment

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

IMNN: Phase 3 Ovarian Cancer Trial to get Underway in Mar 2025…

Performance Overview